Tripeptide neuropeptide

Pinealon

Pinealon is the tripeptide Glu-Asp-Arg; the app lists its half-life as 0.4 hours (about 24 minutes), and none of the 20 PubMed record titles listed describes a measured half-life.1

Emerging evidence (the app's grade, not a conclusion of the sources)Get the app

Level after one dose

Pinealon after one dose: 50% at ~0.4 h, 25% at 0.8 h, 12.5% at 1.2 h.

Drawn from the half-life in the app's model, ~0.4 h. The model's figures

Pinealon is the tripeptide Glu-Asp-Arg, written in the Russian-group literature as the EDR peptide.2 The 2020 review by Khavinson and colleagues describes it as "a tripeptide isolated from the polypeptide neuroprotective drug Cortexin".2 Searching PubMed for "pinealon" returned 22 records, among them cell studies, rat studies, two human reports and reviews, several of them published in the journal Advances in Gerontology.1,3,4,5 Vladimir Khavinson is an author of the 2011 cell study, the 2012 rat study, the 2013 review and the 2020 review, and the first, second and fourth of these carry his affiliation with the Saint Petersburg Institute of Bioregulation and Gerontology.1,3,6,2 The app grades the evidence for pinealon as emerging. No controlled trial in people was identified in ClinicalTrials.gov, and no US prescribing label was identified in DailyMed, in searches for "pinealon".

The papers describe the proposed actions of pinealon as assumptions or possibilities, and most of the mechanistic data come from cultured cells and rats. The 2020 review states that "Presumably, the molecular mechanism of the EDR peptide biological activity, like a number of other short peptides, is associated with its ability to penetrate into the cytoplasm and the cell nucleus and regulate gene expression and synthesis of the corresponding proteins".2 The same review says that "In vitro studies have shown that the EDR peptide interacts with DNA, exerting a destabilizing effect on the secondary structure of a macromolecule", and that molecular modeling "suggested two possible binding sites".2 On antioxidant action, the review reports that the peptide "decreased ROS synthesis caused by the receptor-dependent (ouabain, homocysteine) and non-receptor (hydrogen peroxide) activators of oxidative stress in granular cells of rat cerebellum".2 For other proposed pathways (PI3K/Akt, Nrf2, Keap1, NF-κB) the review states that "this hypothesis requires further investigation and experimental confirmation".2 The review reports that in rats sensitive to hypoxia, giving the peptide raised brain SOD2 and GPx1 activity "to the level of hypoxia-resistant animals".2 The review's funding statement reads "This research received no external funding", its conflict statement reads "Authors declare no conflict of interest", and all four authors are listed at the Saint Petersburg Institute of Bioregulation and Gerontology.2

Deeper analysis: Khavinson and colleagues, Rejuvenation Research, 2011

Khavinson and colleagues, working with Boldyrev and others, reported cell experiments in Rejuvenation Research in 2011.1 The design was in vitro: the record describes "dose-dependent restriction of reactive oxygen species (ROS) accumulation in cerebellar granule cells, neutrophils, and pheochromocytoma (PC12) cells".1 It adds that "pinealon decreases necrotic cell death measured by the propidium iodide test".1 The protective effect was "accompanied with a delayed time course of ERK 1/2 activation and modification of the cell cycle".1 The authors report that effects on ROS and cell death "saturated at lower concentrations, whereas cell cycle modulation continues at higher concentrations", and they conclude that "pinealon is able to interact directly with the cell genome".1 The PubMed record carries no group sizes, concentrations or limitations statement, and its publication type is listed as "Research Support, Non-U.S. Gov't" with no named funder.1 Khavinson is listed at the Saint-Petersburg Institute of Bioregulation and Gerontology.1 These are results in cultured cells and are not results in people.

Deeper analysis: Arutjunyan and colleagues, International Journal of Clinical and Experimental Medicine, 2012

Arutjunyan and colleagues (D.O. Ott Institute of Obstetrics and Gynecology and the Institute of Bioregulation and Gerontology, St. Petersburg, with Khavinson as last author) tested pinealon in the offspring of rats with diet-induced hyperhomocysteinemia.3 The pregnant Wistar rats received pinealon "administered i.p. during 5 days prior to the methionine loading in a daily dose of 10 μg/kg b.w.", and the methods name the pinealon as "Pinealon (Garmonika, Russia)" without stating who funded or supplied it.3 The groups were offspring of untreated pregnancies, of methionine-loaded pregnancies, and of methionine-loaded pregnancies with pinealon, with 6 families per group; the behavioural tests used "Each experimental group consisted of 23 animals".3 In the Morris water maze, the platform search time on the first trial of day two "was 112 sec for the intact animals, and 170 sec for the methionine-loaded ones", and 137 sec in the methionine plus pinealon group, which differed from both other groups at p<0.05.3 By the fifth trial, the authors report that "the differences in the performance of the platform finding between all of the studied experimental groups had annihilated completely".3 In cerebellar neurons taken from the pups, the share of propidium iodide labelled (necrotic) cells was 12.6 ± 1.2% in methionine-loaded pups and 3.4 ± 0.7% in the pinealon group, and after hydrogen peroxide exposure 17.7 ± 2.1% and 7.0 ± 0.9%.3 Plasma total homocysteine in the pups stayed raised in the pinealon group (10.5 ± 0.2 µM against 9.8 ± 0.2 µM with methionine alone and 5.6 ± 0.6 µM in controls, n=4 to 5), and the authors write that "pinealon did not abolish the development of hyperhomocysteinemia".3 The authors write that "one may not exclude some other mechanisms of neuroprotection that are still unknown".3 The text states "The study was partially supported by the RFBR" (Russia), and the text read carries no conflict of interest statement.3 This is a rat study with an intraperitoneal dose, and its results are not results in people.

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.4 h
Bioavailability
60%
Typical dose
5–20 mg/day
Route
Nasal / SubQ / Oral
Time to peak
~0.5 h

The second column holds the app's own figures; the third column shows what the cited papers report.

Table 3.1Half-life and pharmacokinetics4 rows
ParameterApp's figureReported in the papers
Half-life~0.4 h (24 minutes)None of the 20 PubMed record titles listed describes a measured half-life; the app's notes give approximately 15–30 minutes
Bioavailability60%None of the 20 PubMed record titles listed describes a measured bioavailability
Time to peak~0.5 hNo figure for time to peak was identified; the app lists a duration of 3 hours
RoutesNasal, SubQ, oralOral administration in patients is described in the 2020 review2; the 2012 rat study used intraperitoneal injection3; no study of nasal or subcutaneous use was identified in the records listed

No measured figure sits beside the app's half-life, bioavailability or time to peak, so none of the three is confirmed or contradicted here. The level chart is left out because none of the cited papers reports a concentration interval.

4

Human studies

The human reports identified are known here only through PubMed summaries and one review passage, and the 2012 and 2015 records list no affiliations.

Table 4.1Human studies3 rows
Study and yearDesignPeopleDose and lengthMain result
Bashkireva and Artamonova, Advances in Gerontology, 20124Listed in PubMed as a clinical trial; drivers (experimental group) compared with metal craftsmen (control group) on neurotic states; the summary does not say who received the peptides150 male lorry-drivers (mean age 43.3 ± 0.9) and 150 male metal craftsmen (mean age 42.8 ± 0.9)Not stated in the PubMed summaryPeptide application reported to improve psychoemotional indices; best effect from pinealon combined with vezugen, so no pinealon-alone result is given
Meshchaninov and colleagues, Advances in Gerontology, 20155Study of pinealon and vesugen on biological age indicators; no comparator described32 people (18 men, 12 women) aged 41-83 years with polymorbidity and organic brain syndrome in remissionNot stated in the PubMed summaryPinealon and vesugen reported to have an anabolic effect; vesugen reported as more visible; prooxidant activity and lower CD34+ cell markers also reported
Described in the 2020 review by Khavinson and colleagues2Oral pinealon in addition to standard therapy; design, comparator and original paper not given in the passage72 patients with consequences of traumatic brain injury and cerebrastheniaNot stated in the passageReported as improved memory, shorter and less intense headaches, emotional balance and enhanced performance efficacy

Deeper analysis: Bashkireva and Artamonova, 2012

Bashkireva and Artamonova reported in Advances in Gerontology in 2012 a comparison of 150 male lorry-drivers with 150 male metal craftsmen using a clinical questionnaire to identify neurotic states.4 The authors report a predominance of unstable adaptation and borderline mental disorders among the drivers compared with the control group.4 They report that application of bioregulating peptides led to results described as "restore the organism adaptive potential, improved psychoemotional indices, intensified resistance to work stress and reduced occupational risk of borderline mental disorders".4 They state that "The best effect was obtained in case of combined application of several cytogens (pinealon and vezugen)", so a result for pinealon alone is not given in the summary, and the effect of the combination is not a result for pinealon alone.4 The PubMed record gives no dose, route, duration, randomisation, blinding, adverse event data, funding statement or limitations statement, and lists no affiliations.4

Deeper analysis: Meshchaninov and colleagues, 2015

Meshchaninov and colleagues reported in Advances in Gerontology in 2015 that they "estimated the cellular and metabolic part of geroprophylactic effects of short synthetic tripeptides vesugen and pinealon for correction of the biological age".5 The 32 participants were aged 41-83 years, and the summary does not report separate group sizes for the two peptides, a comparator, a dose or a duration.5 The summary reports that "Vesugen has demonstrated more visible geroprophylactic effect than Pinealon".5 The same summary reports "the prooxidant activity through chemiluminescence", a decrease of CD34+ positive hematopoietic polypotent cells that "has shown significant inhibition of hemopoiesis", and no effect on "the degree of chromatin condensation".5 The authors flag the chromatin property for further study in the future.5 The record states no funding, no affiliations and no conflict of interest statement, and these results are pooled across pinealon and vesugen in the summary.5

The 72-patient report described in the 2020 review

The 2020 review by Khavinson and colleagues, written at the Saint Petersburg Institute of Bioregulation and Gerontology, states that oral pinealon in addition to standard therapy in 72 patients with traumatic brain injury consequences and cerebrasthenia "led to improved memory, reduced duration and intensity of headaches, emotional balance, and enhanced performance efficacy".2 The passage gives no comparator, dose, length, effect sizes or adverse events, and the original report was not among the records read.2 A further review by Umnov, Lin'kova and Khavinson (Advances in Gerontology, 2013) is described in PubMed as covering "short peptides (semax, kortagen, pinealon)" and "the data of clinical applying of peptides in elderly and old age people".6

5

Doses reported in studies and on labels

No label gives a pinealon dose, and the human reports cited do not state one in the PubMed records available.

Table 5.1Doses reported in studies and on labels3 rows
SourceDose, route and lengthWho or whatComparator and n
The app's figure5–20 mg/day; routes nasal, SubQ, oralNot tied to a studyNo comparator or n given
Arutjunyan and colleagues, 2012310 μg/kg body weight daily, intraperitoneal, for 5 days before methionine loadingPregnant Wistar ratsMethionine alone and untreated pregnancies; 6 families per group, 23 offspring per group in behavioural tests
2020 review2Oral, dose and length not given72 patients with traumatic brain injury consequences and cerebrastheniaStandard therapy; no comparator described

The rat dose is per kilogram in an animal and the app's range is in milligrams per day, so no conversion between them is made here.

None of the cited papers reports a systematic count of adverse events for pinealon in people. The 2020 review says that "Peptide bioregulators appear to be a promising group of neuroprotectors due to their high physiological activity and absence of side effects", a statement about the class of peptide bioregulators and not a pinealon safety dataset.2 Meshchaninov and colleagues, in a study of 32 people, report prooxidant activity by chemiluminescence and a CD34+ cell decrease that they describe as "significant inhibition of hemopoiesis", for pinealon and vesugen together.5 The same authors write that "Pinealon and Vesugen haven't affected the degree of chromatin condensation, so they are safe on nuclear genetic level".5 In the rat study, the lower weight of pups from methionine-loaded dams (17.86 ± 3.05 g at 10 days against 23.05 ± 1.45 g in controls) was not seen in the pinealon group (25.03 ± 4.86 g); the paper also states that animals that developed under prenatal hyperhomocysteinemia were exceeded in many test results by control animals, and it gives no separate adverse event report for the pinealon group.3

7

Bloodwork and markers

The app lists no markers to monitor for pinealon. The human report by Meshchaninov and colleagues measured chemiluminescence, CD34+ positive cells in blood and chromatin condensation.5 The rat study measured plasma total homocysteine in pups and reported it stayed raised with pinealon.3

8

Regulatory and anti-doping status

The text of the 2026 WADA Prohibited List does not contain the word pinealon.7 The list's class S0 covers "Any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use", which it says is prohibited at all times.7 Whether S0 applies to pinealon depends on its approval status, and no regulator's document on pinealon was identified.

9

What is not known

Sources in this part

  1. 2Khavinson et al., 2020

No study of pinealon was listed in ClinicalTrials.gov; the 2012 report is typed in PubMed as a clinical trial and describes a control group of metal craftsmen, but the two human reports and the review passage described above give no dose and no systematic adverse event count in the records read. None of the 20 PubMed record titles listed describes a measured half-life, bioavailability or time to peak, so the app's figures have no measured figure beside them. No study of nasal or subcutaneous administration was identified among the records listed. Binding to DNA, entry into the cell nucleus and gene-expression effects are described in the review as assumed, presumed or possible.2 Khavinson is an author of four of the six papers read, the 2012 and 2015 human reports list no affiliations, and none of the PubMed record titles listed names an independent replication.

What is pinealon?

Pinealon is the tripeptide Glu-Asp-Arg.1 The 2020 review also calls it the EDR peptide.2

What is the half-life of pinealon?

The app lists a half-life of 0.4 hours, about 24 minutes, and none of the 20 PubMed record titles listed describes a measured half-life.

Is pinealon banned by WADA?

The text of the 2026 WADA Prohibited List does not name pinealon.7 Class S0 covers substances with no current governmental approval for human therapeutic use, so its application depends on approval status.7

Is pinealon approved by the FDA?

No US prescribing label for pinealon was identified in DailyMed.

Has pinealon been tested in people?

Two reports in Advances in Gerontology, from 2012 (150 lorry-drivers and 150 metal craftsmen) and 2015 (32 people aged 41-83), involve pinealon, the 2020 review describes oral pinealon in 72 patients, and no study was listed in ClinicalTrials.gov.4,5,2 The 2012 report combined pinealon with vezugen and the 2015 report studied pinealon with vesugen, so neither is a result for pinealon alone.4,5

What does pinealon do in cells?

In cultured cerebellar granule cells, neutrophils and PC12 cells, pinealon showed dose-dependent restriction of reactive oxygen species accumulation.1 This is a cell result and is not a result in people.

What side effects of pinealon have been reported?

Meshchaninov and colleagues report prooxidant activity by chemiluminescence and a CD34+ cell decrease they call "significant inhibition of hemopoiesis", in 32 people given pinealon and vesugen; the summary does not call these adverse events, and it also states that "Pinealon and Vesugen haven't affected the degree of chromatin condensation, so they are safe on nuclear genetic level".5 No systematic adverse event count for pinealon was identified.

Which routes does the app list for pinealon?

The app lists nasal, SubQ and oral routes. The 2020 review describes oral administration in patients, and the 2012 rat study used intraperitoneal injection.2,3

12

References

  1. Khavinson V, et al. Pinealon increases cell viability by suppression of free radical levels and activating proliferative processes. Rejuvenation Res 2011;14(5):535-41. PMID 21978084
  2. Khavinson V, et al. EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer's Disease. Molecules 2020;26(1):159. PMID 33396470
  3. Arutjunyan A, et al. Pinealon protects the rat offspring from prenatal hyperhomocysteinemia. Int J Clin Exp Med 2012. PMID 22567179
  4. Bashkireva AS, Artamonova VG. The peptide correction of neurotic disorders among professional truck-drivers. Adv Gerontol 2012;25(4):718-28. PMID 23734521
  5. Meshchaninov VN, et al. Effect of synthetic peptides on aging of patients with chronic polymorbidity and organic brain syndrome of the central nervous system in remission. Adv Gerontol 2015;28(1):62-7. PMID 26390612
  6. Umnov RS, Lin'kova NS, Khavinson VKh. Neuroprotective effects of peptides bioregulators in people of various age. Adv Gerontol 2013;26(4):671-8. PMID 24738258
  7. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list